SCHEMBL5459005

SCHEMBL5459005

NC(=O)c1c(NC(=O)C2CCC2)sc2c1CCOC2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.67
CNR2 P34972 3/20 0.62
CFTR P13569 1/20 0.58
ALDH1A1 P00352 5/20 0.57
HSD17B10 Q99714 3/20 0.57
HPGD P15428 2/20 0.57
TSHR P16473 1/20 0.57
MAPK10 P53779 1/20 0.57
MDM2 Q00987 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
KDM4E B2RXH2 4/20 0.56
MAPT P10636 2/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
PTPRC P08575 1/20 0.53
PTPN2 P17706 1/20 0.53
PTPN1 P18031 1/20 0.53
PTPRB P23467 1/20 0.53
PTPRE P23469 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5450973 0.97 FLT3 (0.67) FLT3CNR2CFTRALDH1A1HSD17B10
SCHEMBL5449114 0.96 FLT3 (0.65) FLT3CNR2CFTRALDH1A1HSD17B10
SCHEMBL5444948 0.95 FLT3 (0.70) FLT3CNR2CFTRALDH1A1HSD17B10
SCHEMBL5451370 0.90 CNR2 (0.55) FLT3CNR2CFTRALDH1A1HSD17B10
SCHEMBL5453318 0.88 FLT3 (0.57) FLT3CNR2CFTRALDH1A1HSD17B10
SCHEMBL3760411 0.85 PTPN1 (0.67) FLT3CNR2HSD17B10MEN1KMT2A
SCHEMBL8289515 0.84 FLT3 (0.87) FLT3CNR2ALDH1A1HSD17B10HPGD
SCHEMBL3914689 0.84 FLT3 (0.92) FLT3CNR2ALDH1A1HSD17B10HPGD
SCHEMBL5449075 0.84 CFTR (0.66) FLT3CNR2CFTRALDH1A1HSD17B10
SCHEMBL5453432 0.83 PTPN1 (0.71) FLT3CNR2CFTRHSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885CNR2 2272/4885CFTR 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.